Form 8-K

8-K — Electromed, Inc.

Accession: 0001437749-26-028915

Filed: 2026-08-25

Period: 2026-08-25

CIK: 0001488917

SIC: 3845 (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS)

Item: Results of Operations and Financial Condition

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — elmd20260518_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (ex_964461.htm)

EX-99.2 — EXHIBIT 99.2 (ex_1006919.htm)

EX-99.3 — EXHIBIT 99.3 (ex_1006842.htm)

GRAPHIC (slide01.jpg)

GRAPHIC (slide02.jpg)

GRAPHIC (slide03.jpg)

GRAPHIC (slide04.jpg)

GRAPHIC (slide05.jpg)

GRAPHIC (slide06.jpg)

GRAPHIC (slide07.jpg)

GRAPHIC (slide08.jpg)

GRAPHIC (slide09.jpg)

GRAPHIC (slide10.jpg)

GRAPHIC (slide11.jpg)

GRAPHIC (slide12.jpg)

GRAPHIC (slide13.jpg)

GRAPHIC (slide14.jpg)

GRAPHIC (slide15.jpg)

GRAPHIC (slide16.jpg)

GRAPHIC (slide17.jpg)

GRAPHIC (slide18.jpg)

GRAPHIC (slide19.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: elmd20260518_8k.htm · Sequence: 1

elmd20260518_8k.htm

false

0001488917

2026-08-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 25, 2026

ELECTROMED, INC.

(Exact Name of Registrant as Specified in Its Charter)

Minnesota

001-34839

41-1732920

(State or Other Jurisdiction of

Incorporation)

(Commission File Number)

(I.R.S. Employer Identification

Number)

500 Sixth Avenue NW

New Prague, MN 56071

(Address of Principal Executive Offices) (Zip Code)

(952) 758-9299

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Common Stock, $0.01 par value

ELMD

NYSE American LLC

(Title of each class)

(Trading Symbol)

(Name of each exchange on which registered)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 25, 2026, Electromed, Inc., a Minnesota corporation (the “Company”), issued a press release announcing its financial results for the fourth quarter and fiscal year ended June 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference into this Item 2.02.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 25, 2026, James L. Cunniff, President and Chief Executive Officer of the Company, notified the Company of his intention to retire from the Company effective on or about April 2, 2027. The Board of Directors of the Company (the “Board”) has engaged an executive search firm and is commencing a comprehensive search to identify the Company’s next Chief Executive Officer. Mr. Cunniff is also expected to resign from the Board upon his retirement.

Item 7.01 Regulation FD Disclosure.

The Company has updated its investor presentation, a copy of which is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference into this Item 7.01. The Company intends to use the presentation in whole or in part, in one or more meetings with investors and analysts.

The full text of a press release announcing Mr. Cunniff’s planned retirement is furnished as Exhibit 99.3 to this Current Report on Form 8-K and incorporated by reference into this Item 7.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

Exhibit Number

Description

99.1

Press Release (Earnings Announcement) dated August 25, 2026

99.2

Company Investor Presentation dated August 25, 2026

99.3

Press Release (Executive Succession) dated August 25, 2026

104

Cover Page Interactive Data File (embedded in the cover page and formatted in inline XBRL)

The information contained in Items 2.02 and 7.01 and Exhibits 99.1, 99.2, and 99.3 to this Current Report on Form 8-K shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Cautionary Statement

Certain statements in this Current Report on Form 8-K constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “anticipate,” “assume,” “believe,” “expect,” “may,” “potential,” “should,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown associated with such statements. Examples of risks and uncertainties for the Company include, but are not limited to, our ability to obtain reimbursement from Medicare, Medicaid, or private insurance payers for our products; component or raw material shortages, changes to lead times or significant price increases, inflationary trends in electronic components, and uncertainty related to trade regulations (including, but not limited to, changes to tariffs); adverse changes to state and federal health care regulations; our ability to maintain regulatory compliance and to gain future regulatory approvals and clearances; entry of new competitors including new drug or pharmaceutical discoveries; adverse economic and business conditions or intense competition; wage and component price inflation; rising energy costs and geopolitical conflict; technical problems with our research and products; the risks associated with cyberattacks, data breaches, computer viruses and other similar security threats; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the hospital or homecare distributor channels; adverse international health care regulation impacting current international business; our ability to renew our line of credit or obtain additional credit as necessary; and our ability to protect and expand our intellectual property portfolio, as well as other factors the Company may describe from time to time in its reports filed with the Securities and Exchange Commission (including the Company’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all of the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update them in light of new information or future events.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ELECTROMED, INC.

Date: August 25, 2026

By: /s/ Bradley M. Nagel

Name:

Bradley M. Nagel

Title:

Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: ex_964461.htm · Sequence: 2

ex_964461.htm

Exhibit 99.1

Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results

Strong homecare revenue growth and expanded operating leverage drive record operating income in Fiscal 2026

NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ("Q4 FY 2026") and full year ended June 30, 2026 ("FY 2026").

Q4 FY 2026 Company Highlights

●

Net revenue increased 11.6% to a record $19.4 million in Q4 FY 2026, from $17.4 million in the fourth quarter of the prior fiscal year.

●

Operating income increased 25.8% over the prior year to a record $3.8 million, or 19.7% of net revenues.

●

Net income increased 54.3% to a record $3.4 million, or $0.39 per diluted share, compared to $2.2 million, or $0.25 per diluted share, in the fourth quarter of the prior fiscal year.

FY 2026 Company Highlights

●

Net revenue increased 15.3% to a record $73.8 million in FY 2026, from $64.0 million in the prior fiscal year.

●

Operating income increased 43.7% over the prior year to a record $13.9 million, or 18.8% of net revenues.

●

Net income was $11.3 million, or $1.30 per diluted share, compared to $7.5 million, or $0.85 per diluted share, in the prior fiscal year.

●

Cash provided by operations totaled $9.7 million in FY 2026, compared to $11.4 million in the prior fiscal year.

●

Electromed repurchased $3.9 million of its common stock throughout FY 2026.

“Fiscal 2026 was another exceptional year for Electromed, as the company generated record revenues and profits. The fourth fiscal quarter marked our 15th consecutive quarter of year-over-year revenue and profit growth. Also, our operating margin increased more than 370 basis points over FY 2025, which demonstrates our continued success in driving operational leverage. Our strong financial performance, combined with strategic investments in our sales force, systems, and bronchiectasis market development initiatives, positions us to capitalize on the opportunity to serve the approximately 800,000 diagnosed bronchiectasis patients who could benefit from our SmartVest® therapy. Our robust balance sheet with $20.5 million in cash, and recognition as one of Minnesota’s fastest-growing public companies has Electromed well-positioned for durable, long-term growth and value creation for our investors.”

Q4 FY 2026 Results

All amounts below are for the three months ended June 30, 2026, and compare to the three months ended June 30, 2025.

Net revenues grew 11.6% to $19.4 million from $17.4 million.

Revenue in our direct homecare business increased 15.2% to $17.7 million from $15.4 million. The increase in revenue was primarily due to an increase in direct sales representatives, increased sales representative productivity, and higher net revenues per approval.

Gross profit increased to $15.3 million or 78.7% of net revenues from $13.6 million or 78.3% of net revenues. The increase in gross profit and gross margin was primarily due to increased revenue and higher net revenue per device.

Selling, general and administrative (“SG&A”) expenses were $11.1 million, representing an increase of $0.8 million or 8.3%. The increase in the current period was primarily due to the increased salaries and incentive compensation related to the higher average number of personnel in the sales, sales support, marketing, and reimbursement teams to process higher patient referrals.

Operating income was $3.8 million or 19.7% of net revenues, compared to $3.0 million, or 17.5% of net revenues. This increase in operating income was primarily due to increases in revenue and gross profit.

Net income increased by 54.3% to $3.4 million, or $0.39 per diluted share, compared to $2.2 million, or $0.25 per diluted share.

FY 2026 Summary

All amounts below are for the year ended June 30, 2026 ("fiscal 2026") and compare to the fiscal year ended June 30, 2025 ("fiscal 2025").

Net revenues for fiscal 2026 grew by 15.3% to a record $73.8 million, from $64.0 million in fiscal 2025.

Revenue in our direct homecare market increased year-over-year by 16.3% to $66.6 million, from $57.3 million. The increase in revenue was due to an increase in direct sales representatives, increased sales representative productivity, and higher net revenues per approval. For the year ended June 30, 2026, we averaged 58 homecare field sales representatives. The homecare revenue per weighted average direct sales representative was $1,145,000, exceeding Electromed's target range for the year of $1,000,000 to $1,100,000.

Revenue in our non-homecare business grew to $7.2 million in fiscal 2026, an increase of $0.5 million, or 6.7%, from $6.7 million in fiscal 2025. The increase was primarily due to increased distributor and hospital revenue.

Gross profit increased to $57.9 million, or 78.5% of net revenues in fiscal 2026, from $50.0 million, or 78.1% of net revenues, in fiscal 2025. The increase in gross profit and gross margin was primarily due to increased revenue and higher net revenue per device.

Selling, general and administrative (“SG&A”) expenses were $42.7 million in fiscal 2026, representing an increase of $3.4 million or 8.7% from $39.3 million in fiscal 2025. The increase was primarily due to increased salaries and incentive compensation related to the higher average number of personnel in the sales, sales support, marketing, and reimbursement teams to process more patient referrals.

Operating income was $13.9 million or 18.8% of net revenues in fiscal 2026, compared to $9.7 million, or 15.1% of net revenues in fiscal 2025. This increase in operating income was primarily due to increases in net revenues and gross profit.

Net income for fiscal 2026 was $11.3 million, or $1.30 per diluted share, compared to $7.5 million, or $0.85 per diluted share in fiscal 2025.

As of June 30, 2026, Electromed had $20.5 million in cash, $29.8 million in accounts receivable and no debt, achieving working capital of $45.1 million and total shareholders’ equity of $54.0 million. The cash balance reflects an increase of $5.2 million for the twelve months ended June 30, 2026, compared to a decrease in cash of $0.8 million in the twelve months ended June 30, 2025. The increase in cash for the twelve months ended June 30, 2026, was driven primarily by positive operating cash flow of $9.7 million, partially offset by share repurchases of $3.9 million of Electromed common stock.

Conference Call and Webcast Information

The conference call with members of Electromed management will be held at 5:00 p.m. Eastern Time on Tuesday, August 25, 2026.

Interested parties may participate in the call by dialing (877) 407-3982 (Domestic) or (201) 493-6780 (International).

The live conference call webcast will be accessible in the Investor Relations section of Electromed’s website and directly via the following link: https://viavid.webcasts.com/starthere.jsp?ei=1770216&tp_key=c0342b57c3

For those who cannot listen to the live broadcast, a replay will be available by dialing (844) 512-2921 (Domestic) or (412) 317-6671 (International) and referencing the replay pin number 13761827. Additionally, an online replay will be available for at least one year in the Investor Relations section of Electromed’s web site at: https://investors.smartvest.com/events-and-presentations/default.aspx

About Electromed, Inc.

Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.

Cautionary Statements

Certain statements in this press release constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “continue,” “expect,” “may,” “plan,” “potential,” “should,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown, associated with such statements. Examples of risks and uncertainties for Electromed include, but are not limited to, our ability to obtain reimbursement from Medicare, Medicaid, or private insurance payers for our products; component or raw material shortages, changes to lead times or significant price increases, inflationary trends in electronic components, and uncertainty related to trade regulations (including, but not limited to, changes to tariffs); adverse changes to state and federal health care regulations; our ability to maintain regulatory compliance and to gain future regulatory approvals and clearances; entry of new competitors including new drug or pharmaceutical discoveries; adverse economic and business conditions or intense competition; wage and component price inflation; rising energy costs and geopolitical conflict; technical problems with our research and products; the risks associated with cyberattacks, data breaches, computer viruses and other similar security threats; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the hospital or homecare distributor channels; adverse international health care regulation impacting current international business; our ability to renew our line of credit or obtain additional credit as necessary; and our ability to protect and expand our intellectual property portfolio, as well as other factors we may describe from time to time in Electromed’s reports filed with the Securities and Exchange Commission (including Electromed’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.

Brad Nagel, Chief Financial Officer

(952) 758-9299

investorrelations@electromed.com

Mike Cavanaugh, Investor Relations

ICR Healthcare

(617) 877-9641

mike.cavanaugh@icrhealthcare.com

Source: Electromed, Inc.

Electromed, Inc.

Condensed Balance Sheets

As of June 30,

2026

2025

Assets

Current Assets

Cash and cash equivalents

20,450,000

15,287,000

Accounts receivable (net of allowances for credit losses of $45,000)

29,805,000

24,660,000

Contract assets

1,094,000

1,036,000

Inventories

3,681,000

3,299,000

Prepaid expenses and other current assets

1,170,000

392,000

Income tax receivable

1,168,000

408,000

Total current assets

57,368,000

45,082,000

Property and equipment, net

5,214,000

4,714,000

Finite-life intangible assets, net

379,000

371,000

Other assets

1,270,000

1,173,000

Deferred income taxes

2,036,000

2,462,000

Total assets

66,267,000

53,802,000

Liabilities and Shareholders’ Equity

Current Liabilities

Accounts payable

2,643,000

2,667,000

Accrued compensation

6,071,000

5,079,000

Warranty reserve

1,899,000

1,645,000

Other accrued liabilities

1,609,000

1,077,000

Total current liabilities

12,222,000

10,468,000

Other long-term liabilities

66,000

125,000

Total liabilities

12,288,000

10,593,000

Shareholders’ Equity

Common stock, $0.01 par value per share, 13,000,000 shares authorized; 8,366,163 and 8,349,176 shares issued and outstanding, as of June 30, 2026, and June 30, 2025, respectively

84,000

83,000

Additional paid-in capital

25,331,000

21,941,000

Retained earnings

28,564,000

21,185,000

Total shareholders’ equity

53,979,000

43,209,000

Total liabilities and shareholders’ equity

66,267,000

53,802,000

Electromed, Inc.

Condensed Statements of Operations

Three Months Ended

Year Ended

June 30,

2026

2025

2026

2025

(Unaudited)

Net revenues

19,417,000

17,393,000

73,776,000

64,000,000

Cost of revenues

4,133,000

3,769,000

15,833,000

14,029,000

Gross profit

15,284,000

13,624,000

57,943,000

49,971,000

Operating expenses

Selling, general and administrative

11,131,000

10,282,000

42,748,000

39,315,000

Research and development

328,000

302,000

1,314,000

996,000

Total operating expenses

11,459,000

10,584,000

44,062,000

40,311,000

Operating income

3,825,000

3,040,000

13,881,000

9,660,000

Interest income, net

136,000

135,000

479,000

624,000

Net income before income taxes

3,961,000

3,175,000

14,360,000

10,284,000

Income tax expense

560,000

971,000

3,059,000

2,747,000

Net income

3,401,000

2,204,000

11,301,000

7,537,000

Income per share:

Basic

0.41

0.26

1.37

0.89

Diluted

0.39

0.25

1.30

0.85

Weighted-average common shares outstanding:

Basic

8,258,440

8,334,821

8,266,071

8,454,100

Diluted

8,734,188

8,718,900

8,688,563

8,914,421

Electromed, Inc.

Condensed Statements of Cash Flows

Years Ended June 30,

2026

2025

Cash Flows from Operating Activities

Net income

11,301,000

7,537,000

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation

868,000

1,039,000

Impairment of intangible assets

—

212,000

Amortization

208,000

133,000

Share-based compensation expense

2,722,000

3,059,000

Deferred income taxes

426,000

(310,000

)

Changes in operating assets and liabilities:

Accounts receivable

(5,145,000

)

(1,327,000

)

Contract assets

(58,000

)

(317,000

)

Inventories

(517,000

)

175,000

Prepaid expenses and other assets

(1,024,000

)

(959,000

)

Income tax receivable, net

(760,000

)

(685,000

)

Accounts payable and accrued liabilities

652,000

1,650,000

Accrued compensation

992,000

1,186,000

Net cash provided by operating activities

9,665,000

11,393,000

Cash Flows from Investing Activities

Expenditures for property and equipment

(1,252,000

)

(262,000

)

Expenditures for finite-life intangible assets

(48,000

)

(44,000

)

Net cash used for investing activities

(1,300,000

)

(306,000

)

Cash Flows from Financing Activities

Issuance of common stock upon exercise of options

965,000

398,000

Taxes paid on net share settlement of stock awards

(249,000

)

(2,278,000

)

Repurchase of common stock

(3,918,000

)

(10,000,000

)

Net cash used for financing activities

(3,202,000

)

(11,880,000

)

Net increase (decrease) in cash

5,163,000

(793,000

)

Cash and cash equivalents

Beginning of period

15,287,000

16,080,000

End of period

20,450,000

15,287,000

EX-99.2 — EXHIBIT 99.2

EX-99.2

Filename: ex_1006919.htm · Sequence: 3

Image Exhibit

Exhibit 99.2

Electromed, Inc. Investor Presentation August 25, 2026 NYSE American: ELMD Innovation Leader in Airway Clearance Technologies

Slide 2: Forward looking statements - Certain statements in this presentation constitute forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “anticipate,” “believe,” “committed,” “continue,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown associated with such statements. Examples of risks and uncertainties for Electromed include, but are not limited to, our ability to obtain reimbursement from Medicare, Medicaid, or private insurance payers for our products; component or raw material shortages, changes to lead times or significant price increases, inflationary trends in electronic components, and uncertainty related to trade regulations (including, but not limited to, changes to tariffs); adverse changes to state and federal health care regulations; our ability to maintain regulatory compliance and to gain future regulatory approvals and clearances; entry of new competitors including new drug or pharmaceutical discoveries; adverse economic and business conditions or intense competition; wage and component price inflation; rising energy costs and geopolitical conflict; technical problems with our research and products; the risks associated with cyberattacks, data breaches, computer viruses and other similar security threats; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the hospital or homecare distributor channels; adverse international health care regulation impacting current international business; our ability to renew our line of credit or obtain additional credit as necessary; and our ability to protect and expand our intellectual property portfolio, as well as other factors we may describe from time to time in Electromed’s reports filed with the Securities and Exchange Commission (including Electromed’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.

Slide 3: Electromed – Who We Are - Electromed, Inc. is a growing medical device company focused on airway management to help people around the world breathe better, stay healthier, and lead active and fulfilling lives. Key Stats: Headquarters: New Prague, MN Ticker: ELMD Manufacturing: Minnesota, USA Established: 1992 Treatment Focus: HFCWO Employees: 197* LTM Net Revenues: $73.8M* Market Cap: $350M* Cash / Debt: $20.5M / $0.0M* *As of and for the 12 months ended 06/30/2026

Electromed Highlights ● Growing and profitable medical technology company ● A leader in the large and expanding airway clearance market ● The SmartVest® Airway Clearance System’s High Frequency Chest Wall Oscillation (“HFCWO”) technology supported by clinical outcomes data with strong reimbursement. ● Attractive direct-to-patient and provider model ● Strong financial profile with attractive gross margins and well-capitalized balance sheet 35% Operating Income CAGR* *FY ‘21 through FY26 FY21: Operating Income: $3.1M Revenue: $35.8M FY22: Operating Income: $3.0M Revenue: $41.7M FY23: Operating Income: $4.0M Revenue: $48.1M FY24: Operating Income: $6.5M Revenue: $54.7M FY25: Operating Income: $9.7M Revenue: $64.0M FY26: Operating Income: $13.9M Revenue: $73.8M

What is Bronchiectasis (BE)? BE is a condition that is prevalent, but underdiagnosed and often misdiagnosed ● Irreversible, chronic lung condition where airways become abnormally widened ● Caused by impaired ability to clear mucus, which leads to recurrent inflammation and infections ● Mean prevalence of Bronchiectasis in patients with COPD is 54%¹ 1.Chalmers J. and Sethi S. Raising awareness of Bronchiectasis in primary care: overview of diagnosis and management strategies in adults. NPJ Prim Care Respir Med. 2017;27:18. Disease Misdiagnosed – Disease Underdiagnosed – HFCWO Under-prescribed Normal airways, lungs in cross-section, widened airways – normal airway – airway wall – muscle Airway with bronchiectasis – widened airway, mucus, scarred and thickened airway wall

U.S. Market: Large, Growing, Underpenetrated The Company is expanding awareness within the large BE patient population ~166K HFCWO Adopted - Estimated HFCWO Bronchiectasis penetration, treated population1 Bronchiectasis HFCWO penetration ~16%1 ~$3.1B - Estimated Revenue Opportunity for HFCWO Within Primary Pulmonology Callpoint2 ((1 million – 166K) x 35% x $10.5K) = $3.1B2 ~1 million U.S. BE Diagnosed - Estimated Net Bronchiectasis Prevalence, Diagnosed3 Diagnosed BE population has grown at ~12% annually3 4.1 Million U.S. Undiagnosed - Potential Total Addressable Market - $15.1B (4.1M x $10.5K) - Estimated Bronchiectasis Prevalence, Undiagnosed With COPD / BE Overlap4 35% of BE patients managed by pulmonologists3 1. Internal company estimates derived from GUIDEHOUSE 2023 NASM claims database, GUIDEHOUSE 2023 literature review and 2024 S2N HFCWO Claims data. 2. Internal company estimates derived from GUIDEHOUSE 2023 NASM claims database. 35% of BE patients managed by pulmonologists and $10.5K represents the assumed HFCWO ASP. 3. Internal company estimates derived from GUIDEHOUSE 2023 NASM claims database. 4. Internal company estimates derived from GUIDEHOUSE 2023 literature review and 2023 CDC NHANES data.

How is Bronchiectasis Treated? HFCWO therapy mimics manual Chest Percussion Therapy (CPT) 1. Clear Airways FirstTM With SmartVest® 2. Treat The Infection (Antibiotics) 3. Reduce The Inflammation (Anti-Inflammatories) On average, HFCWO therapy is performed as follows: 2x per day, 15 minutes per session, 7 days a week How does SmartVest® HFCWO therapy work? Air-pulse technology – a generator delivers repeating pulses of air through a single hose to an inflated wearable vest. Gentle squeeze and release – each pulse gently squeezes and releases the chest to thin and loosen mucus in the lungs. Airway clearance – mucus is propelled upward toward major airways where it can be coughed and more easily. Airway clearance – smartvest – reduce inflammation – treat infection – complete bronchiectasis care

SmartVest ® Clearway HFCWO designed with the patient in mind SmartVest® has a well-established reimbursement code from CMS – E0483; the Company estimates it has over 275 million contracted lives in the U.S. An Enhanced Patient Experience - Sleek and lightweight generator - Intuitive user interface for better patient adherence - More portable and easier for travel

SmartNotes™ Patient Progress Report - Tracking patient outcomes and treatment progress to physicians SmartNotes combines patient Quality of Life and Therapy Utilization data to provide physicians with extended views into disease management ● Proactive, ongoing support: Licensed Respiratory Therapists stay connected with patients and support their therapy utilization ● Outcomes Management: Easy-to-read report provides physicians with a comprehensive view of therapy impact

Clinical Evidence & Patient Satisfaction - HFCWO therapy is effective in treating BE patients “Therapy with SmartVest® significantly decreased exacerbations requiring hospitalization, antibiotic use, and stabilizes lung function” - Powner 94% Of patients would recommend the SmartVest® to others3 97% Of patients report feeling better or the same after SmartVest® use3 99% Of patients report an increase in sputum production3 57% Reduction in antibiotic prescriptions1 59% Decrease in hospitalizations1 75% Fewer emergency department visits2 1. Sievert CE, et al 2016. Using High Frequency Chest Wall Oscillation in a Bronchiectasis Patient Population: An Outcomes-Based Case Review. Respiratory Therapy, 11(4), 34-38. 2. Sievert CE, et al 2018. Incidence of Bronchiectasis-Related Exacerbation Rates After HFCWO Treatment—A Longitudinal Outcome-Based Study, Respiratory Therapy, 13(2), 38-41. 3. Patient data on file. “Therapy with HFCWO demonstrated key health outcomes improved in post- compared to pre-index period: cough, all-cause hospitalizations, pneumonia, and pulmonary hospitalizations” - DeKoven

Direct-to-Patient Model - Drives an attractive margin profile Electromed expects 78% gross margins to continue improving going forward Traditional Medical Equipment Channel: Manufacturer > Home Medical Equipment (HME) Distributor > Patient Direct-to-Patient Distribution (Electromed): Electromed > Patient

Net Revenue Breakdown - $73.8M (FY’26) By Setting: 94% Home Care (Includes $3.3 million from home care distributor revenue), 5% Hospitals, 1% Other Homecare by Payer: 50% Commercial/Other (Includes Managed Medicare and Managed Medicaid), 48% Medicare, 2% Medicaid Homecare Qualified Referral Volume: 76% Bronchiectasis, 19% Neuromuscular, 3% Cystic Fibrosis, 2% Other

Electromed Growth Strategy - Leveraging commercial team and reimbursement expertise to accelerate growth Electromed, Inc: ● Protect and grow homecare core o Protect and grow Homecare core with current strategy (sales force expansion, payor contracting, market development) as well as converting low prescribers to high prescribers and target high BE diagnosing physicians who are not prescribing SmartVest® ● Expand into natural adjacencies o Leverage existing technology platform – Pediatrics and Hospital (leveraging DTC and GPO contracts) ● Acquisition opportunities o Explore potential inorganic acquisition opportunities

Capital Allocation Strategy: Proven execution against the Company’s priorities Capital Allocation: Organic Business Growth > Generate Free Cash Flow > Potential Strategic Investments or Return to Shareholders FY2026 Execution: ● New Technology & CAPEX investments ● Sales rep expansion ● Market development ● Treat SMART from the Start campaign ● Payor coverage expansion $3.9 million of shares repurchased in FY26

Why invest? Large, expanding chronic lung diseases market, clinically proven technology, broad payor coverage, consistent double-digit organic revenue growth, high gross margins, robust cash flow and expanding operating leverage

Performance vs. Russell Medical Equipment Index (TTM and as of 6/30/2026 Results): Sales Growth: ELMD 15.3% > RUS ME 9.8% Gross Margin: ELMD 78.5% > RUS ME 53.9% Operating Margin: ELMD 18.8% > RUS ME (2.4)%

Electromed, Inc.: Jim Cunniff, President & CEO, (952) 758-9299, jcunniff@electromed.com – Brad Nagel, CFO, (952) 758-9299, bnagel@electromed.com ICR Healthcare: Mike Cavanaugh, (617) 877-8641, mike.cavanaugh@icrhealthcare.com

Appendix

Financial Highlights (in $ millions, except share amounts) Year Ended June 30, 2025: Revenues $64.0 Gross Profit $50.0 Gross Margin 78.1% Operating Income $9.7 Operating Margin 15.1% Net Income $7.5 Diluted EPS $0.85 Diluted Shares 8,914,421 Cash Provided by Operations $11.4 Year Ended June 30, 2026: Revenues $73.8 Gross Profit $57.9 Gross Margin 78.5% Operating Income $13.9 Operating Margin 18.8% Net Income $11.3 Diluted EPS $1.30 Diluted Shares 8,688,563 Cash Provided by Operations $9.7

EX-99.3 — EXHIBIT 99.3

EX-99.3

Filename: ex_1006842.htm · Sequence: 4

ex_1006842.htm

Exhibit 99.3

Electromed Announces CEO’s Planned Retirement

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that Jim Cunniff expects to retire as President and Chief Executive Officer, on or about April 2, 2027. Upon his retirement, he will resign from the Company’s Board of Directors. The Board of Directors intends to conduct a national search for Electromed’s next President and Chief Executive Officer and has engaged an executive search firm to assist in the process.

Mr. Cunniff has served as the Company’s President and Chief Executive Officer and as a member of its Board of Directors since 2023. During his tenure, he has strengthened Electromed’s position as a leader in HFCWO airway clearance technology, has delivered consistent double-digit net revenues growth and significant operating margin expansion, which has led to improved shareholder value.

“It has been an honor to lead Electromed over the last three years. Our company just delivered its 15th consecutive quarter of year-over-year revenue and profit growth, has a talented and successful leadership team, and is well positioned for continued success. I look forward to working with the board and management team over the coming months to identify an exemplary leader for our business and help ensure a successful transition.”

“On behalf of the board, I would like to thank Jim for his positive impact on our business, the patients we serve, and our shareholders during his tenure as CEO and a member of our board,” said Kathleen Skarvan, Chair of the Board of Directors. “The board is committed to selecting a world-class successor, and we are grateful to have his continued leadership and guidance throughout this transition process.”

About Electromed, Inc.

Cautionary Statements

Certain statements in this press release, including the timing and outcomes of potential executive transitions, constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “expect,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown, associated with such statements. Examples of risks and uncertainties for the company include, but are not limited to, our ability to obtain reimbursement from Medicare, Medicaid, or private insurance payers for our products; component or raw material shortages, changes to lead times or significant price increases, inflationary trends in electronic components, and uncertainty related to trade regulations (including, but not limited to, changes to tariffs); adverse changes to state and federal health care regulations; our ability to maintain regulatory compliance and to gain future regulatory approvals and clearances; entry of new competitors including new drug or pharmaceutical discoveries; adverse economic and business conditions or intense competition; wage and component price inflation; rising energy costs and geopolitical conflict; technical problems with our research and products; the risks associated with cyberattacks, data breaches, computer viruses and other similar security threats; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the hospital or homecare distributor channels; adverse international health care regulation impacting current international business; our ability to renew our line of credit or obtain additional credit as necessary; and our ability to protect and expand our intellectual property portfolio, as well as other factors we may describe from time to time in the company’s reports filed with the Securities and Exchange Commission (including the company’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all of the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.

Contacts

Brad Nagel, Chief Financial Officer

(952) 758-9299

investorrelations@electromed.com

Mike Cavanaugh, Investor Relations

ICR Westwicke

(617) 877-9641

mike.cavanaugh@westwicke.com

GRAPHIC

Filename: slide01.jpg · Sequence: 9

Binary file (47744 bytes)

Download slide01.jpg

GRAPHIC

Filename: slide02.jpg · Sequence: 10

Binary file (81029 bytes)

Download slide02.jpg

GRAPHIC

Filename: slide03.jpg · Sequence: 11

Binary file (51742 bytes)

Download slide03.jpg

GRAPHIC

Filename: slide04.jpg · Sequence: 12

Binary file (54627 bytes)

Download slide04.jpg

GRAPHIC

Filename: slide05.jpg · Sequence: 13

Binary file (66678 bytes)

Download slide05.jpg

GRAPHIC

Filename: slide06.jpg · Sequence: 14

Binary file (75564 bytes)

Download slide06.jpg

GRAPHIC

Filename: slide07.jpg · Sequence: 15

Binary file (60640 bytes)

Download slide07.jpg

GRAPHIC

Filename: slide08.jpg · Sequence: 16

Binary file (68862 bytes)

Download slide08.jpg

GRAPHIC

Filename: slide09.jpg · Sequence: 17

Binary file (72675 bytes)

Download slide09.jpg

GRAPHIC

Filename: slide10.jpg · Sequence: 18

Binary file (72354 bytes)

Download slide10.jpg

GRAPHIC

Filename: slide11.jpg · Sequence: 19

Binary file (53184 bytes)

Download slide11.jpg

GRAPHIC

Filename: slide12.jpg · Sequence: 20

Binary file (54966 bytes)

Download slide12.jpg

GRAPHIC

Filename: slide13.jpg · Sequence: 21

Binary file (64697 bytes)

Download slide13.jpg

GRAPHIC

Filename: slide14.jpg · Sequence: 22

Binary file (59053 bytes)

Download slide14.jpg

GRAPHIC

Filename: slide15.jpg · Sequence: 23

Binary file (45260 bytes)

Download slide15.jpg

GRAPHIC

Filename: slide16.jpg · Sequence: 24

Binary file (44348 bytes)

Download slide16.jpg

GRAPHIC

Filename: slide17.jpg · Sequence: 25

Binary file (42058 bytes)

Download slide17.jpg

GRAPHIC

Filename: slide18.jpg · Sequence: 26

Binary file (22405 bytes)

Download slide18.jpg

GRAPHIC

Filename: slide19.jpg · Sequence: 27

Binary file (52959 bytes)

Download slide19.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 29

v3.26.1

Document And Entity Information

Aug. 25, 2026

Document Information [Line Items]

Entity, Registrant Name

ELECTROMED, INC.

Document, Type

8-K

Document, Period End Date

Aug. 25, 2026

Entity, Incorporation, State or Country Code

Entity, File Number

001-34839

Entity, Tax Identification Number

41-1732920

Entity, Address, Address Line One

500 Sixth Avenue NW

Entity, Address, City or Town

New Prague

Entity, Address, State or Province

Entity, Address, Postal Zip Code

56071

City Area Code

952

Local Phone Number

758-9299

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock

Trading Symbol

ELMD

Security Exchange Name

NYSE

Entity, Emerging Growth Company

false

Amendment Flag

false

Entity, Central Index Key

0001488917

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_DocumentInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration